Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia

ClinicalTrials.gov ID

NCT07384702

Lead Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

230Estimated

Last Update Posted

Feb 5, 2026Actual

Start Date

Jun 2026Estimated

Primary Completion Date

Jun 2030Estimated

Completion Date

Jun 2030Estimated

Official Title

Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)

Brief Summary

The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).

Detailed Description

The CLOPI-SNAP study evaluates whether the administration of clopidogrel as adjunctive therapy improves clinical outcomes while maintaining an acceptable safety profile in hospitalized patients with Staphylococcus aureus bacteremia (SAB).

To be eligible for the SNAP platform (NCT 05137119), patients must meet at least two criteria: isolation of the Staphylococcus aureus complex from ≥1 blood culture and admission to a participating hospital at the time of eligibility assessment. SNAP is designed to concurrently evaluate multiple therapeutic strategies. Patients are randomly assigned to different concurrent treatment options that are currently considered acceptable in routine clinical practice; thus, standard-of-care therapy consists of approved antibiotics for the treatment of Staphylococcus aureus infection.

Specifically, patients participating in CLOPI-SNAP-adult patients with SAB enrolled in the SNAP platform-are randomized in a 1:1 ratio to receive either oral clopidogrel for 5 days, administered as a 300-mg loading dose on Day 1 followed by 75 mg once daily on subsequent days, or no antiplatelet therapy. The primary endpoint is the Desirability of Outcome Ranking (DOOR) assessed at Day 90, a hierarchical composite outcome integrating survival, clinical failure, infectious complications, and the occurrence of serious adverse events. The limited 5-day duration of clopidogrel administration is intended to focus its potential therapeutic benefit on the early phase of infection, characterized by high bacterial burden and systemic inflammation, while minimizing the risk of bleeding associated with prolonged antiplatelet exposure.

• Bacteremia Due to Staphylococcus Aureus

• Clopidogrel
• No antiplatelet treatment

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

To be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria:

• Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture.
• Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment.
• Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture.

Exclusion Criteria:

General Medical and Safety Factors:

• Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine).
• Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C).
• Pregnancy: Pregnant or breastfeeding women.

High Risk of Bleeding or Hematologic Disorders:

• Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days.
• Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment.
• Coagulation parameters: Platelet count <50,000/mm³ or known coagulation disorders.
• Concomitant medications: Patients already receiving regular aspirin therapy, other P2Y12 inhibitors, or therapeutic-dose anticoagulants (prophylactic-dose heparin is permitted).

Specific Diagnoses and Clinical Criteria:

• Endocarditis: Confirmed diagnosis or clinical suspicion of bacterial endocarditis. Sources indicate that exclusion of endocarditis is justified because the potential benefit of clopidogrel is expected during early phases of high bacterial burden, whereas bleeding risk increases with prolonged treatment or established deep-seated infections.
• Medical judgment: If the treating clinical team determines that participation in this domain is not in the patient's best interest.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER

Collaborators

University of MelbourneOTHER

asoriano@clinic.cat+34 932275708

lboix@mutuaterrassa.cat ; luciaboix@hotmail.com+34 936784872

mmontero@psmar.cat+34 932483251 ext. 3251

fescrihuela@bellvitgehospital.cat+34932606948

sarris.grillo@gmail.com

nufernan@gmail.com+34 932746000 ext. 6090

isabelm.machuca.sspa@juntadeandalucia.es+34 957 011 636

miparedro@gmail.com+34 958992536

ruben.lobato27@gmail.com+34 665 816 722

bdiazp@salud.madrid.org

carmenmaria.saez@salud.madrid.org+34 619515031

mariadolores.corbacho@salud.madrid.org

marial.martin@ssib.es

erecachavillamor@gmail.com+34635927009

josemolinagb@gmail.com+34 671590280

nicolasmerchante@gmail.com+34 95501734

francisco.arnaizlasrevillas@scsalud.es+34 942202520 ext. 73263

nuria.val.dominguez@gmail.com

joserrapa@gmail.com+34 630585111

• Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

  NCT06650488

  RecruitingInterventionalPhase 4Updated Mar 20, 2026
• Staphylococcus Aureus Network Adaptive Platform Trial

  NCT05137119

  RecruitingInterventionalPhase 4Updated May 6, 2026
• Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

  NCT05184764

  CompletedInterventionalPhase 1Phase 2Updated Mar 23, 2026
• Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

  NCT00714961

  CompletedInterventionalPhase 3Updated Mar 25, 2009
• Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

  NCT06650501

  RecruitingInterventionalPhase 4Updated Mar 20, 2026
• Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned

  NCT00821834

  CompletedInterventionalPhase 3Updated Jul 26, 2011